Thalidomide-Induced Severe Neutropenia during Treatment of Multiple Myeloma

Yutaka Hattori, Tsunayuki Kakimoto, Shinichiro Okamoto, Norihide Sato, Yasuo Ikeda

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Recent reports have shown that thalidomide has antiangiogenic activity and is effective for the treatment of refractory multiple myeloma. Unlike other antineoplastic drugs, thalidomide is reported to rarely cause severe hematologic toxicity. In Keio University Hospital, 44 patients with refractory multiple myeloma, including 18 who had relapsed after hematopoietic stem cell transplantation, were treated with this drug as a single agent. Severe grade 3 or 4 neutropenia during thalidomide treatment was observed in 10 patients. This phenomenon was not noted in previous reports. Neutropenia usually occurred in the first or second week of treatment. Concomitant progression of thrombocytopenia occurred in 5 cases, and bone marrow hypoplasia without a significant increase in myeloma cell numbers was also observed in 5 cases. Neutropenia was not correlated with antitumor response or the plasma concentration of thalidomide but was more frequently observed in patients with a low neutrophil and platelet count, anemia, or a high plasma cell percentage in the bone marrow before thalidomide treatment. Thus, this drug should be used carefully for patients with pretreatment cytopenia or a high tumor burden in the bone marrow.

Original languageEnglish
Pages (from-to)283-288
Number of pages6
JournalInternational Journal of Hematology
Volume79
Issue number3
Publication statusPublished - 2004 Apr

Fingerprint

Thalidomide
Neutropenia
Multiple Myeloma
Bone Marrow
Therapeutics
Hematopoietic Stem Cell Transplantation
Plasma Cells
Tumor Burden
Platelet Count
Thrombocytopenia
Pharmaceutical Preparations
Antineoplastic Agents
Anemia
Neutrophils
Cell Count

Keywords

  • Hematopoietic stem cell
  • Multiple myeloma
  • Neutropenia
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Thalidomide-Induced Severe Neutropenia during Treatment of Multiple Myeloma. / Hattori, Yutaka; Kakimoto, Tsunayuki; Okamoto, Shinichiro; Sato, Norihide; Ikeda, Yasuo.

In: International Journal of Hematology, Vol. 79, No. 3, 04.2004, p. 283-288.

Research output: Contribution to journalArticle

Hattori, Yutaka ; Kakimoto, Tsunayuki ; Okamoto, Shinichiro ; Sato, Norihide ; Ikeda, Yasuo. / Thalidomide-Induced Severe Neutropenia during Treatment of Multiple Myeloma. In: International Journal of Hematology. 2004 ; Vol. 79, No. 3. pp. 283-288.
@article{ab147f05afef483fb8549fadc75905a1,
title = "Thalidomide-Induced Severe Neutropenia during Treatment of Multiple Myeloma",
abstract = "Recent reports have shown that thalidomide has antiangiogenic activity and is effective for the treatment of refractory multiple myeloma. Unlike other antineoplastic drugs, thalidomide is reported to rarely cause severe hematologic toxicity. In Keio University Hospital, 44 patients with refractory multiple myeloma, including 18 who had relapsed after hematopoietic stem cell transplantation, were treated with this drug as a single agent. Severe grade 3 or 4 neutropenia during thalidomide treatment was observed in 10 patients. This phenomenon was not noted in previous reports. Neutropenia usually occurred in the first or second week of treatment. Concomitant progression of thrombocytopenia occurred in 5 cases, and bone marrow hypoplasia without a significant increase in myeloma cell numbers was also observed in 5 cases. Neutropenia was not correlated with antitumor response or the plasma concentration of thalidomide but was more frequently observed in patients with a low neutrophil and platelet count, anemia, or a high plasma cell percentage in the bone marrow before thalidomide treatment. Thus, this drug should be used carefully for patients with pretreatment cytopenia or a high tumor burden in the bone marrow.",
keywords = "Hematopoietic stem cell, Multiple myeloma, Neutropenia, Thalidomide",
author = "Yutaka Hattori and Tsunayuki Kakimoto and Shinichiro Okamoto and Norihide Sato and Yasuo Ikeda",
year = "2004",
month = "4",
language = "English",
volume = "79",
pages = "283--288",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Thalidomide-Induced Severe Neutropenia during Treatment of Multiple Myeloma

AU - Hattori, Yutaka

AU - Kakimoto, Tsunayuki

AU - Okamoto, Shinichiro

AU - Sato, Norihide

AU - Ikeda, Yasuo

PY - 2004/4

Y1 - 2004/4

N2 - Recent reports have shown that thalidomide has antiangiogenic activity and is effective for the treatment of refractory multiple myeloma. Unlike other antineoplastic drugs, thalidomide is reported to rarely cause severe hematologic toxicity. In Keio University Hospital, 44 patients with refractory multiple myeloma, including 18 who had relapsed after hematopoietic stem cell transplantation, were treated with this drug as a single agent. Severe grade 3 or 4 neutropenia during thalidomide treatment was observed in 10 patients. This phenomenon was not noted in previous reports. Neutropenia usually occurred in the first or second week of treatment. Concomitant progression of thrombocytopenia occurred in 5 cases, and bone marrow hypoplasia without a significant increase in myeloma cell numbers was also observed in 5 cases. Neutropenia was not correlated with antitumor response or the plasma concentration of thalidomide but was more frequently observed in patients with a low neutrophil and platelet count, anemia, or a high plasma cell percentage in the bone marrow before thalidomide treatment. Thus, this drug should be used carefully for patients with pretreatment cytopenia or a high tumor burden in the bone marrow.

AB - Recent reports have shown that thalidomide has antiangiogenic activity and is effective for the treatment of refractory multiple myeloma. Unlike other antineoplastic drugs, thalidomide is reported to rarely cause severe hematologic toxicity. In Keio University Hospital, 44 patients with refractory multiple myeloma, including 18 who had relapsed after hematopoietic stem cell transplantation, were treated with this drug as a single agent. Severe grade 3 or 4 neutropenia during thalidomide treatment was observed in 10 patients. This phenomenon was not noted in previous reports. Neutropenia usually occurred in the first or second week of treatment. Concomitant progression of thrombocytopenia occurred in 5 cases, and bone marrow hypoplasia without a significant increase in myeloma cell numbers was also observed in 5 cases. Neutropenia was not correlated with antitumor response or the plasma concentration of thalidomide but was more frequently observed in patients with a low neutrophil and platelet count, anemia, or a high plasma cell percentage in the bone marrow before thalidomide treatment. Thus, this drug should be used carefully for patients with pretreatment cytopenia or a high tumor burden in the bone marrow.

KW - Hematopoietic stem cell

KW - Multiple myeloma

KW - Neutropenia

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=2442534173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442534173&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 283

EP - 288

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -